Discover how hVIVO's recruitment division sets the gold standard in clinical trials, delivering efficient, tailored participant sourcing for diverse studies...
hVIVO has showcased its excellence in clinical research by successfully executing a large-scale flu vaccine trial, demonstrating agility and operational expertise under tight deadlines...
hVIVO plc announces the release of its 2024 Annual Report and upcoming AGM, along with notable board changes, including the departure of key directors...
Investing in clinical research with FluCamp means supporting innovative healthcare solutions while ensuring participant welfare through unique trial methodologies...
Discover hVIVO's groundbreaking studies on immunomodulators presented at ESCMID 2025, revealing insights into viral infections and host immune responses...
Asthma affects millions, but with the right management and support from FluCamp, individuals can embrace exercise for better health. Discover more today!..
Discover hVIVO's groundbreaking RSV-B London strain, a pivotal advancement in respiratory virus research, enhancing vaccine and antiviral development for RSV...
Navigating first-in-human trials requires precision. Learn how integrating real-world patient insights, like cannabis use, enhances drug development for schizophrenia...
Discover how FluCamp pioneers clinical trials, bridging lab discoveries and revolutionary treatments, ensuring safety and efficacy in modern medicine...
hVIVO plc reports impressive audited results for 2024, showcasing a revenue increase and strong EBITDA growth in the human challenge clinical trial sector...
hVIVO plc (LON:HVO), a leader in human challenge clinical trials, will announce its 2024 results on April 10, 2025, with an analyst briefing to follow...
hVIVO plc, a leader in human challenge clinical trials, has acquired Cryo-Store Limited to enhance its biobank and laboratory services with advanced storage solutions...
hVIVO expands its clinical footprint by acquiring CRS, a German CRO, adding Phase I & II trial capabilities in Europe, enhancing strategic growth for 2025-2026...
Discover how hVIVO's recruitment division sets the gold standard in clinical trials, delivering efficient, tailored participant sourcing for diverse studies...
hVIVO has showcased its excellence in clinical research by successfully executing a large-scale flu vaccine trial, demonstrating agility and operational expertise under tight deadlines...
hVIVO plc announces the release of its 2024 Annual Report and upcoming AGM, along with notable board changes, including the departure of key directors...
Investing in clinical research with FluCamp means supporting innovative healthcare solutions while ensuring participant welfare through unique trial methodologies...
Discover hVIVO's groundbreaking studies on immunomodulators presented at ESCMID 2025, revealing insights into viral infections and host immune responses...
Asthma affects millions, but with the right management and support from FluCamp, individuals can embrace exercise for better health. Discover more today!..
Discover hVIVO's groundbreaking RSV-B London strain, a pivotal advancement in respiratory virus research, enhancing vaccine and antiviral development for RSV...
Navigating first-in-human trials requires precision. Learn how integrating real-world patient insights, like cannabis use, enhances drug development for schizophrenia...
Discover how FluCamp pioneers clinical trials, bridging lab discoveries and revolutionary treatments, ensuring safety and efficacy in modern medicine...
hVIVO plc reports impressive audited results for 2024, showcasing a revenue increase and strong EBITDA growth in the human challenge clinical trial sector...
hVIVO plc (LON:HVO), a leader in human challenge clinical trials, will announce its 2024 results on April 10, 2025, with an analyst briefing to follow...
hVIVO plc, a leader in human challenge clinical trials, has acquired Cryo-Store Limited to enhance its biobank and laboratory services with advanced storage solutions...
hVIVO expands its clinical footprint by acquiring CRS, a German CRO, adding Phase I & II trial capabilities in Europe, enhancing strategic growth for 2025-2026...
